000277316 001__ 277316
000277316 005__ 20240229155014.0
000277316 0247_ $$2doi$$a10.1111/pcmr.13104
000277316 0247_ $$2pmid$$apmid:37390098
000277316 0247_ $$2ISSN$$a1755-1471
000277316 0247_ $$2ISSN$$a0893-5785
000277316 0247_ $$2ISSN$$a1600-0749
000277316 0247_ $$2ISSN$$a1755-148X
000277316 0247_ $$2altmetric$$aaltmetric:150800031
000277316 037__ $$aDKFZ-2023-01334
000277316 041__ $$aEnglish
000277316 082__ $$a610
000277316 1001_ $$00000-0002-9607-3866$$aThierauf, Julia C$$b0$$eFirst author
000277316 245__ $$aPrognostic biomarkers for survival in mucosal melanoma.
000277316 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2023
000277316 3367_ $$2DRIVER$$aarticle
000277316 3367_ $$2DataCite$$aOutput Types/Journal article
000277316 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692801081_16395
000277316 3367_ $$2BibTeX$$aARTICLE
000277316 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277316 3367_ $$00$$2EndNote$$aJournal Article
000277316 500__ $$a#EA:A102# / 2023 Sep;36(5):378-387
000277316 520__ $$aMucosal melanoma (MM) is a rare subtype of melanoma with an aggressive clinical course. In cutaneous melanoma (CM), the absence of pigmentation and presence of NRAS/KRAS mutations are biomarkers indicating an aggressive clinical course with shorter overall survival. Similar data for MM are missing. We present the real-world outcome data in a cohort of genotyped MM patients and assessed the prognostic relevance of pigmentation- and NRAS/KRAS mutation status. We correlated pathological reports and clinical data with overall survival of patients with MM. Furthermore, we performed clinically integrated molecular genotyping and analyzed real world treatment regimens for covariates associated with clinical outcome. We identified 39 patients with available clinical and molecular data. Patients with amelanotic MM had a significantly shorter overall survival (p = .003). In addition, the presence of a NRAS or KRAS mutation was significantly associated with poor overall survival (NRAS or KRAS p = .024). Currently, it is unknown if the same prognostic relevance for the lack of pigmentation and RAS mutations in CM, exists in MM. Here we analyzed a cohort of MM for outcome measures and determined that two known prognostic biomarkers for CM are in fact novel prognosticators for MM.
000277316 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000277316 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277316 650_7 $$2Other$$agenotyping
000277316 650_7 $$2Other$$amucosal melanoma
000277316 650_7 $$2Other$$apigmentation
000277316 650_7 $$2Other$$aprognostic biomarkers
000277316 7001_ $$aKaluziak, Stefan T$$b1
000277316 7001_ $$aCodd, Elizabeth$$b2
000277316 7001_ $$aDybel, Stacy N$$b3
000277316 7001_ $$aJobbagy, Soma$$b4
000277316 7001_ $$aPurohit, Rashi$$b5
000277316 7001_ $$aFarahani, Alex A$$b6
000277316 7001_ $$aDedeilia, Aikaterini$$b7
000277316 7001_ $$aNaranbhai, Vivek$$b8
000277316 7001_ $$aHoang, Mai P$$b9
000277316 7001_ $$00000-0002-4742-8165$$aFisch, Adam S$$b10
000277316 7001_ $$aRitterhouse, Lauren$$b11
000277316 7001_ $$aBoland, Genevieve M$$b12
000277316 7001_ $$aLennerz, Jochen K$$b13
000277316 7001_ $$aIafrate, A John$$b14
000277316 773__ $$0PERI:(DE-600)2425880-5$$a10.1111/pcmr.13104$$gp. pcmr.13104$$n5$$p378-387$$tPigment cell & melanoma research$$v36$$x1755-1471$$y2023
000277316 909CO $$ooai:inrepo02.dkfz.de:277316$$pVDB
000277316 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-9607-3866$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000277316 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000277316 9141_ $$y2023
000277316 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-29$$wger
000277316 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-29
000277316 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-29
000277316 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-29
000277316 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPIGM CELL MELANOMA R : 2022$$d2023-10-25
000277316 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
000277316 9201_ $$0I:(DE-He78)A102-20160331$$kA102$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000277316 9200_ $$0I:(DE-He78)A102-20160331$$kA102$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000277316 980__ $$ajournal
000277316 980__ $$aVDB
000277316 980__ $$aI:(DE-He78)A102-20160331
000277316 980__ $$aUNRESTRICTED